Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
:COYA
COYA Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
COYA Stock 12 Month Forecast
Average Price Target
$17.75
▲(216.96% Upside)
| Highest Price Target$20.00 | Average Price Target$17.75 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$18
Buy
221.43%
Upside
Reiterated
12/11/25
Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost ProspectsValuation and Risks. We employ a discounted cash flow (DCF)-based valuation methodology to assess Coya's prospects. This utilizes a 12% discount rate and 2% terminal growth rate, while applying a 15% probability of approval to COYA 302 in AD and a 20% probability to this candidate in the ALS indication. We also apply a 21% effective tax rate.
Lake Street
$17
Buy
203.57%
Upside
Reiterated
12/10/25
BTIG
$15→$16
Buy
185.71%
Upside
Reiterated
12/09/25
Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302We see the trial as relatively risk-reduced (as much as anything in ALS can be) after the initial ALS pilot study halted disease progression in patients who were steadily declining at baseline—replicating this in larger cohorts would be transformational. For context, a 30% slowing of decline is typically viewed as clinically meaningful in progressive diseases. Following extensive FDA engagement, the IND was resubmitted. Management has noted the agency treated it as a novel therapeutic, not merely a combination of two biosimilars for approved products. Accordingly, management believes their tox package is sufficient to support a BLA, assuming the upcoming trial demonstrates efficacy and safety.
Lucid Capital
$20
Buy
257.14%
Upside
Reiterated
09/22/25
Chardan Capital
$14
Buy
150.00%
Upside
Reiterated
07/01/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$18
Buy
221.43%
Upside
Reiterated
12/11/25
Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost ProspectsValuation and Risks. We employ a discounted cash flow (DCF)-based valuation methodology to assess Coya's prospects. This utilizes a 12% discount rate and 2% terminal growth rate, while applying a 15% probability of approval to COYA 302 in AD and a 20% probability to this candidate in the ALS indication. We also apply a 21% effective tax rate.
Lake Street
$17
Buy
203.57%
Upside
Reiterated
12/10/25
BTIG
$15→$16
Buy
185.71%
Upside
Reiterated
12/09/25
Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302We see the trial as relatively risk-reduced (as much as anything in ALS can be) after the initial ALS pilot study halted disease progression in patients who were steadily declining at baseline—replicating this in larger cohorts would be transformational. For context, a 30% slowing of decline is typically viewed as clinically meaningful in progressive diseases. Following extensive FDA engagement, the IND was resubmitted. Management has noted the agency treated it as a novel therapeutic, not merely a combination of two biosimilars for approved products. Accordingly, management believes their tox package is sufficient to support a BLA, assuming the upcoming trial demonstrates efficacy and safety.
Lucid Capital
$20
Buy
257.14%
Upside
Reiterated
09/22/25
Chardan Capital
$14
Buy
150.00%
Upside
Reiterated
07/01/25
Best Analysts Covering Coya Therapeutics, Inc.
1 Month
xxx
Success Rate
7/15 ratings generated profit
Average Return
+5.08%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +5.08% per trade.
3 Months
xxx
Success Rate
11/15 ratings generated profit
Average Return
+18.03%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +18.03% per trade.
1 Year
Success Rate
10/15 ratings generated profit
Average Return
+35.11%
reiterated a buy rating 6 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +35.11% per trade.
2 Years
xxx
Success Rate
9/15 ratings generated profit
Average Return
+18.81%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +18.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
COYA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Nov 25
Dec 25
Strong Buy
8
9
13
12
12
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
9
13
12
12
Each month's total comprises the sum of three months' worth of ratings.
COYA Financial Forecast
COYA Stock Forecast FAQ
What is COYA’s average 12-month price target, according to analysts?
Based on analyst ratings, Coya Therapeutics, Inc.’s 12-month average price target is 17.75.
What is COYA’s upside potential, based on the analysts’ average price target?
Coya Therapeutics, Inc. has 216.96% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is COYA a Buy, Sell or Hold?
Coya Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Coya Therapeutics, Inc.’s price target?
The average price target for Coya Therapeutics, Inc. is 17.75. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 216.96% Increase from the current price of $5.6.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 216.96% Increase from the current price of $5.6.
What do analysts say about Coya Therapeutics, Inc.?
Coya Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of COYA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.